NCT02013167 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 134
- group Id
- BG001
- value
- 271
- group Id
- BG002
- value
- 405
- units
- Participants
- groups
- description
- Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh\*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy. Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\*/CRi could continue to receive SOC therapy for an additional 12 months.
- id
- BG000
- title
- Standard of Care Chemotherapy
- description
- Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh\*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab. Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period. The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles.
- id
- BG001
- title
- Blinatumomab
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 17.3
- value
- 41.1
- group Id
- BG001
- spread
- 17.1
- value
- 40.8
- group Id
- BG002
- spread
- 17.2
- value
- 40.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 124
- group Id
- BG002
- value
- 184
- title
- < 35 years
- categories
- measurements
- group Id
- BG000
- value
- 33
- group Id
- BG001
- value
- 80
- group Id
- BG002
- value
- 113
- title
- 35 to 54 years
- categories
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 60
- title
- 55 to 64 years
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 33
- group Id
- BG002
- value
- 48
- title
- ≥ 65 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 57
- group Id
- BG001
- value
- 109
- group Id
- BG002
- value
- 166
- title
- Female
- measurements
- group Id
- BG000
- value
- 77
- group Id
- BG001
- value
- 162
- group Id
- BG002
- value
- 239
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 37
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 122
- group Id
- BG001
- value
- 243
- group Id
- BG002
- value
- 365
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 5
- title
- American Indian or Alaska Native
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 28
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 8
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 112
- group Id
- BG001
- value
- 228
- group Id
- BG002
- value
- 340
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Multiple
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 20
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 123
- group Id
- BG002
- value
- 183
- title
- < 35 years
- categories
- measurements
- group Id
- BG000
- value
- 74
- group Id
- BG001
- value
- 148
- group Id
- BG002
- value
- 222
- title
- ≥ 35 years
- param Type
- NUMBER
- title
- Age Stratification at Randomization
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 164
- group Id
- BG002
- value
- 244
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 107
- group Id
- BG002
- value
- 161
- title
- No
- param Type
- NUMBER
- title
- Prior Salvage Therapy Stratification at Randomization
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 94
- group Id
- BG002
- value
- 140
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 88
- group Id
- BG001
- value
- 177
- group Id
- BG002
- value
- 265
- title
- No
- param Type
- NUMBER
- title
- Prior Allogeneic Hematopoietic Stem Cell Transplant (HCST)
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 56
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 56
- title
- FLAG ± anthracycline
- categories
- measurements
- group Id
- BG000
- value
- 30
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 30
- title
- High-dose methotrexate
- categories
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 26
- title
- Clofarabine
- categories
- measurements
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 22
- title
- HIDAC
- description
- FLAG = fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor (filgrastim); HiDAC = high-dose cytarabine arabinoside
- param Type
- NUMBER
- title
- Standard of Care Chemotherapy Regimen Received
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 134
- group Id
- BG001
- value
- 271
- group Id
- BG002
- value
- 405
- units
- Participants
- groups
- description
- Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh\*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy. Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\*/CRi could continue to receive SOC therapy for an additional 12 months.
- id
- BG000
- title
- Standard of Care Chemotherapy
- description
- Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh\*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab. Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh\*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period. The initial dose of blinatumomab was 9 μg/day for the first 7 days of treatment, increased to 28 μg/day starting on day 8 through day 29 and for all subsequent cycles.
- id
- BG001
- title
- Blinatumomab
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 17.3
- value
- 41.1
- group Id
- BG001
- spread
- 17.1
- value
- 40.8
- group Id
- BG002
- spread
- 17.2
- value
- 40.9
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 124
- group Id
- BG002
- value
- 184
- title
- < 35 years
- categories
- measurements
- group Id
- BG000
- value
- 33
- group Id
- BG001
- value
- 80
- group Id
- BG002
- value
- 113
- title
- 35 to 54 years
- categories
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 34
- group Id
- BG002
- value
- 60
- title
- 55 to 64 years
- categories
- measurements
- group Id
- BG000
- value
- 15
- group Id
- BG001
- value
- 33
- group Id
- BG002
- value
- 48
- title
- ≥ 65 years
- param Type
- NUMBER
- title
- Age, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 57
- group Id
- BG001
- value
- 109
- group Id
- BG002
- value
- 166
- title
- Female
- measurements
- group Id
- BG000
- value
- 77
- group Id
- BG001
- value
- 162
- group Id
- BG002
- value
- 239
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 11
- group Id
- BG001
- value
- 26
- group Id
- BG002
- value
- 37
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 122
- group Id
- BG001
- value
- 243
- group Id
- BG002
- value
- 365
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 3
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 5
- title
- American Indian or Alaska Native
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 28
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Native Hawaiian or Other Pacific Islander
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 8
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 112
- group Id
- BG001
- value
- 228
- group Id
- BG002
- value
- 340
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- title
- Multiple
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 12
- group Id
- BG002
- value
- 20
- title
- Other
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 60
- group Id
- BG001
- value
- 123
- group Id
- BG002
- value
- 183
- title
- < 35 years
- categories
- measurements
- group Id
- BG000
- value
- 74
- group Id
- BG001
- value
- 148
- group Id
- BG002
- value
- 222
- title
- ≥ 35 years
- param Type
- NUMBER
- title
- Age Stratification at Randomization
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 80
- group Id
- BG001
- value
- 164
- group Id
- BG002
- value
- 244
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 54
- group Id
- BG001
- value
- 107
- group Id
- BG002
- value
- 161
- title
- No
- param Type
- NUMBER
- title
- Prior Salvage Therapy Stratification at Randomization
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 94
- group Id
- BG002
- value
- 140
- title
- Yes
- categories
- measurements
- group Id
- BG000
- value
- 88
- group Id
- BG001
- value
- 177
- group Id
- BG002
- value
- 265
- title
- No
- param Type
- NUMBER
- title
- Prior Allogeneic Hematopoietic Stem Cell Transplant (HCST)
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 56
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 56
- title
- FLAG ± anthracycline
- categories
- measurements
- group Id
- BG000
- value
- 30
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 30
- title
- High-dose methotrexate
- categories
- measurements
- group Id
- BG000
- value
- 26
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 26
- title
- Clofarabine
- categories
- measurements
- group Id
- BG000
- value
- 22
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 22
- title
- HIDAC
- description
- FLAG = fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor (filgrastim); HiDAC = high-dose cytarabine arabinoside
- param Type
- NUMBER
- title
- Standard of Care Chemotherapy Regimen Received
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle